AMG 386, an Angiogenesis Inhibitor, in the Treatment of Recurrent Ovarian, Peritoneal or Fallopian Tube Carcinoma

CME test	Downloadable PDF	PowerPoint slides	CME Information and Faculty Disclosures
Read Dr Love's original email (from June 30, 2010)			Subscribe to Dr Love's email alerts

Slides from a presentation at ASCO 2010 and transcribed comments from a recent interview with Robert A Burger, MD (6/16/10)

 

Karlan BY et al. Randomized, double-blind, placebo-controlled, Phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. Proc ASCO 2010;Abstract 5000.

Go to previous Journal Club